Mesh Bio is a pioneering digital health company harnessing computational biology and digital twin technology to transform chronic disease management. Named to the Forbes Asia 100 to Watch list in 2024, we empower healthcare providers with HealthVector®, the world’s first clinically approved digital twin Software as a Medical Device (SaMD) for predictive and personalized preventive care in diabetes.  

HealthVector® leverages a transparent mechanistic approach powered by computational biology to create patient digital twins, enabling early risk prediction for metabolic diseases such as diabetes and kidney disease. Our solutions provide actionable insights that support precision prevention strategies, improving patient outcomes while reducing the burden on healthcare systems.  

DARA®, our health intelligence platform that powers HealthVector, and the applications in care delivery. DARA consolidates patient data from multiple sources, applies advanced analytics, and generates real-time clinical insights to support physicians in making data-driven decisions. By automating health screening workflows and enhancing clinical decision support, DARA bridges the gap between fragmented health data and proactive care, enabling more effective chronic disease prevention and management.  

With leadership in preventive health screening automation and clinical decision support, HealthVector® and the DARA® enhances care delivery, streamlines provider workflows, and enables a data-driven approach to population health management. Mesh Bio’s solutions have been adopted by the leading healthcare providers across Singapore, Indonesia, Malaysia and Philippines; shaping the future of precision medicine and preventive care.